2110-5820-3-15 2110-5820 Review <p>Understanding brain dysfunction in sepsis</p> SonnevilleRomainromain.sonneville@bch.aphp.fr VerdonkFranckfranck.verdonk@pasteur.fr RauturierCamillecamille.rauturier@pasteur.fr KleinFIsabelleisabelle.klein@bch.aphp.fr WolffMichelmichel.wolff@bch.aphp.fr AnnaneDjillalidjillali.annane@rpc.aphp.fr ChretienFabricefabrice.chretien@pasteur.fr SharsharTarektarek.sharshar@rpc.aphp.fr

Univ Paris Diderot, Sorbonne Paris Cité, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat–Claude-Bernard, Service de Réanimation Médicale et des Maladies Infectieuses, 46, rue Henri-Huchard Cedex 18, Paris 75877, France

Histopathologie Humaine et Modèles Animaux, Département Infection et Epidémiologie, Institut Pasteur, Paris, France

Univ Paris Diderot, Sorbonne Paris Cité, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat–Claude-Bernard, Service de Radiologie, 46, rue Henri-Huchard Cedex 18, Paris 75877, France

Réanimation medico-chirurgicale et EA4342, Hôpital Raymond Poincaré, Université de Versailles Saint-Quentin en Yvelines, Garches, France

Annals of Intensive Care 2110-5820 2013 3 1 15 http://www.annalsofintensivecare.com/content/3/1/15 10.1186/2110-5820-3-1523718252
178201230420132952013 2013Sonneville et al.; licensee Springer.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Delirium Brain dysfunction Sepsis

Abstract

Sepsis often is characterized by an acute brain dysfunction, which is associated with increased morbidity and mortality. Its pathophysiology is highly complex, resulting from both inflammatory and noninflammatory processes, which may induce significant alterations in vulnerable areas of the brain. Important mechanisms include excessive microglial activation, impaired cerebral perfusion, blood–brain-barrier dysfunction, and altered neurotransmission. Systemic insults, such as prolonged inflammation, severe hypoxemia, and persistent hyperglycemia also may contribute to aggravate sepsis-induced brain dysfunction or injury. The diagnosis of brain dysfunction in sepsis relies essentially on neurological examination and neurological tests, such as EEG and neuroimaging. A brain MRI should be considered in case of persistent brain dysfunction after control of sepsis and exclusion of major confounding factors. Recent MRI studies suggest that septic shock can be associated with acute cerebrovascular lesions and white matter abnormalities. Currently, the management of brain dysfunction mainly consists of control of sepsis and prevention of all aggravating factors, including metabolic disturbances, drug overdoses, anticholinergic medications, withdrawal syndromes, and Wernicke’s encephalopathy. Modulation of microglial activation, prevention of blood–brain-barrier alterations, and use of antioxidants represent relevant therapeutic targets that may impact significantly on neurologic outcomes. In the future, investigations in patients with sepsis should be undertaken to reduce the duration of brain dysfunction and to study the impact of this reduction on important health outcomes, including functional and cognitive status in survivors.

Review

Sepsis often is characterized by an early and acute encephalopathy, which is associated with increased morbidity and mortality 1 2 . Patients present with fluctuating mental status changes, inattention, disorganized thinking and therefore match with current criteria for delirium. Delirium is a multifactorial syndrome and several risk factors have been identified during critical illness, including patients’ characteristics (e.g., older age, cognitive impairment), the severity of illness, environmental factors (e.g., sleep deprivation, noisy environment), medications (e.g., benzodiazepines, opioids), and common metabolic disturbances, such as fever, dysnatremias, hypoglycemia, and possibly hyperglycemia 3 4 5 . Among the myriad of conditions that can induce delirium in critical illness, sepsis, in the form of sepsis-associated encephalopathy (SAE), represents the most frequent and severe cause 6 7 . Diagnosing brain dysfunction in a patient with sepsis implies a systematic diagnostic approach of all potential factors, in addition to sepsis, that can contribute to aggravate or prolong brain dysfunction. The purpose of this review is to provide an overview of brain dysfunction in sepsis focusing on pathophysiology, diagnosis, and potential strategies to improve neurologic outcomes.

Pathophysiology

Brain signaling and microglial activation

The encephalopathy in sepsis is considered a diffuse cerebral dysfunction as a consequence of the systemic inflammatory response to an infection, with no direct central nervous system infection (Figure 1). The response to stress is physiologically triggered by an activating signal that is mediated by two pathways. The first one is the vagus nerve, which can detect visceral inflammation through its axonal cytokines receptors: inflammatory products produced in damaged tissues activate afferent signals that are relayed to the nucleus tractus solitarius in the brainstem. Subsequent activation of vagus efferent activity inhibits cytokine synthesis in damaged tissues through a cholinergic anti-inflammatory pathway (the inflammatory reflex) 8 . The vagus nerve is also connected to other autonomic nuclei, notably the paraventricular nucleus that controls adrenal axis and vasopressin secretion 9 . The second pathway involves the circumventricular organs (CVOs), which are located near neuroendocrine and neurovegetative nuclei. CVOs are deprived of a blood–brain barrier (BBB) and express components of innate and adaptive immune systems. Once visceral or systemic inflammation is detected by the first or the second pathway, the activating signal will spread to behavioral, neuroendocrine, and neurovegetative centers. Sepsis enhances the transcription of several pro- and anti-inflammatory cytokines and chemokines in the brain, including tumor necrosis factor alpha (TNFα), interleukin-1 beta (IL1β), transforming growth factor beta (TGF β), and monocyte chemoattractant protein 1 (MCP1) 10 . These mediators modulate the expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and N-methyl-D-aspartate receptors (NMDARs) on neurons, inducing brain dysfunction 11 . Recent studies have suggested the novel importances of IL1β and High Mobility Group Box 1 on the development of cognitive impairment in sepsis survivors 12 13 . These cytokines also modulate NMDARs, with functional consequences on cognition and behavior 14 .

<p>Figure 1</p>

The response of the brain to systemic infection is physiologically triggered by an activating signal that is mediated by three pathways

The response of the brain to systemic infection is physiologically triggered by an activating signal that is mediated by three pathways. 1) The neural pathway that requires activation of primary afferent nerves, such as the vagal or the trigeminal nerves, by involving peripherally produced pathogen-associated molecular patterns (PAMPs) and cytokines. 2) The humoral pathway involves circulating cytokines. They reach the brain at the level of the choroid plexus and the circumventricular organs that lie outside the blood–brain barrier (BBB). 3) The blood–brain barrier alterations induced by the activation of cerebral endothelial cells results in the release of various mediators into the brain. This activation is due to the production, at the early phase of sepsis, of nitric oxide synthase-derived nitric oxide. All of these pathways instigate the activation of microglial cells, which are the resident immune cells of the brain. When activated, microglial cells may negatively affect the brain by the production of nitric oxide, cytokines, and reactive oxygen species that lead to cell death within vulnerable areas of the brain. This production is, in itself, responsible for an increase of the BBB alterations, thus causing a vicious circle of increasing brain dysfunction and injury. These mechanisms are compounded by common metabolic disturbances that occur in septic patients (such as prolonged hyperglycemia, severe hypoxemia), hemodynamic failure, use of medications, and iatrogenic and environmental factors. Septic-associated brain dysfunction may be associated with neurologic sequelae in survivors, including functional and cognitive decline, probably by neurodegenerative and/or ischemic mechanisms.

Microglial activation may represent one of the earliest changes observed in sepsis-associated encephalopathy and prolonged microglial activation may negatively affect other brain cells 15 . Early microglial activation in sepsis was evidenced in mice models within 4 hours following LPS injection, as assessed by the increased proinflammatory cytokine IL1β level in microglia 16 . Using Positron Emission Tomography (PET) imaging in nonhuman primates, another study demonstrated microglia activation only 1h after LPS-induced systemic inflammation 17 . Moreover, experimental studies suggest that aging may increase the intensity of microglial activation and the production proinflammatory cytokines in the hippocampus, notably IL1β 18 19 . The IL1β-mediated inflammatory process in the hippocampus was confirmed in different models of systemic inflammation, including cecal ligation and puncture and peripheral surgery 20 21 . Numerous experimental studies suggest that these proinflammatory mediators released in the central nervous system at the onset of sepsis will in turn lead to neuronal loss within vulnerable areas of the brain, including the hippocampus 22 23 24 . Collectively, these findings represent a neuropathological basis for persistent cognitive impairment, hippocampal atrophy, and electroencephalographic changes observed in sepsis survivors 25 .

Endothelial activation and blood–brain barrier dysfunction

Sepsis induces activation of cerebral endothelial cells, which result in BBB dysfunction and release of various mediators into the brain. Experimental data indicate that at the early phase of sepsis, endothelial nitric oxide synthase-derived nitric oxide exhibits proinflammatory characteristics and contributes to the activation and dysfunction of cerebrovascular endothelial cells 26 . The activated endothelium relays the inflammatory response into the brain by releasing proinflammatory cytokines and NO that are able to interact with surrounding brain cells. The other consequences of endothelial activation may include microcirculatory dysfunction, which might compromise cerebral perfusion 27 . Other studies suggest that endotoxemia leads to inflammation in brain, with alteration in BBB, up-regulation of aquaporin 4 (AQP4) and associated edema, neutrophil infiltration, astrocyte activation, as well as apoptotic cell death, all of which appear to be mediated by TNF-alpha signaling through TNF-receptor 1 28 . Alterations of BBB also have been evidenced in patients with septic shock, with help of brain MRI 29 . BBB breakdown can be localized in the cortex around the Virchow-Robin spaces or have a more diffuse pattern in the whole white matter. It also can predominate in posterior lobes, being consistent with a posterior reversible encephalopathy syndrome 30 . Noninvasive assessment by MRI allowed the identification of new aspects of brain damage in experimental models of sepsis, including cytotoxic and vasogenic edema as well as neuronal damage. These findings highlight the potential applications of MRI techniques for the diagnostic and therapeutic studies in sepsis 31 . Finally, BBB alterations might facilitate the passage of potential neurotoxic factors from the peripheral circulation to the brain. For instance, plasma tryptophan levels are associated with delirium in critically ill patients 32 33 . More recently, increased kynurenine pathway activation, assessed by plasma kynurenine and kynurenine/tryptophan ratio, was found to be associated with fewer days without acute brain dysfunction 33 .

Endothelial activation alters vascular tone and induces both microcirculatory dysfunction and coagulopathy, which will in turn favor ischemic and/or hemorrhagic lesions 34 . Neuropathological studies performed in nonsurvivors of septic shock suggest that ischemia is consistently observed in brain areas susceptible to low cerebral flow and that hemorrhages can be found in approximately 10% of cases 34 35 . Furthermore, it has been recently shown that SAE is rather associated with disturbed autoregulation than with altered cerebral blood flow or tissue oxygenation 36 .

Deficit in cholinergic function and alteration of neurotransmission

Deficits in cholinergic function have been postulated to cause delirium and cognitive decline 37 . Global hypocholinergia result from several mechanisms, including impaired acetylcholine synthesis and cholinergic synaptic dysfunction (impairment of presynaptic, synaptic, or postsynaptic functions of acetylcholine). Nicotinic receptors within the brain bind acetylcholine to modulate cognitive functioning, arousal learning, and memory. Use of anesthetic drugs that decrease acetylcholine release (e.g., isoflurane) may impact on cognitive function after surgery 38 . Anticholinergic medications and their metabolites also may induce delirium through competitive antagonism of postsynaptic muscarinic receptors that are more widely distributed throughout the brain. It was recently demonstrated that chronic cholinergic hypoactivity in the basal forebrain represents a major factor of acute brain dysfunction under systemic inflammation 39 .

Other significant neurotransmitter alterations have been described during experimental sepsis, involving brain beta-adrenergic, gamma-aminobutyric acid, and serotoninergic pathways 40 . These phenomena seem to predominate in cortex and in hippocampus, and may be mediated by NO, cytokines and prostaglandins 41 . Neurotransmitter balance also is altered by different circulating molecules, such as ammonium, tyrosine, tryptophan, and phenylalanine, whose plasma levels are increased secondary to liver dysfunction and muscle proteolysis 42 . Imbalance between dopaminergic and cholinergic neurotransmission is considered a major mechanism of delirium in critically ill patients. It also has been hypothesized that reduced cholinergic inhibition of microglia is involved in delirium 15 . However, administration of rivastigmine, a pharmacological agent that may restore cholinergic control of microglia, did not decrease duration of delirium and might have increased mortality of critically ill patients with delirium 43 . Data from studies performed in critically ill patients receiving prolonged mechanical ventilation also suggest that use of GABA-agonists, such as benzodiazepines, is associated with an increased risk of brain dysfunction 44 . Noradrenergic neurotransmission also might be particularly involved in SAE as dexmedetomidine, a selective agonist of alpha2-adrenoceptors expressed in the locus coeruleus, is associated with less brain dysfunction and better outcomes in septic patients compared with midazolam 45 46 . These findings were recently confirmed in a recent, multicenter trial, where dexmedetomidine compared with midazolam, improved patient’s ability to communicate 47 . Beneficial effects of dexmedetomidine notably include significant preconditioning and postconditioning effects against ischemic brain injury 48 49 . More recent experimental data suggested that neuroprotective effects of dexmedetomidine against glutamate-induced cell death were mediated by an increase in astrocyte expression of brain-derived neurotrophic factor through an extracellular signal-regulated kinase-dependent pathway 50 .

Oxidative stress, mitochondrial dysfunction, and apoptosis

Experimental data suggest that oxidative damage, assessed by the thiobarbituric acid reactive species and the protein carbonyl assays, occurs early (after 6 hours) in the course of sepsis 51 . Moreover, the combined use of antioxidants (N-acetyl-cysteine and deferoxamine) attenuates oxidative damage in hippocampus 6 hours after sepsis induction 52 . Mitochondrial-mediated apoptosis has been evidenced in experimental sepsis and might be related to a decrease of intracellular anti-apoptotic (bcl-2) and an increase of pro-apoptotic (bax) factors 22 . In patients who had died from septic shock, neuronal and microglial apoptosis have been detected in neurovegetative and neuroendocrine nuclei as well as in amygdala 35 . Intensity of apoptosis correlated with expression of endothelial iNOS. Recent data suggested that Caspase-3 is involved in part in apoptosis in the dentate gyrus cell layer of the hippocampus in septic rats 53 . Additionally to nitric oxide, other pro-apoptotic factors have been incriminated, such as glutamate, TNFα, and hyperglycemia 54 .

Prolonged inflammation and other systemic insults

A recent study performed in critically ill patients suggested that high baseline inflammatory biomarkers of systemic inflammation at admission, such as C-reactive protein and procalcitonin, predicted prolonged periods of acute brain dysfunction, irrespective of whether patients had sepsis or not 55 . In another study performed in 50 patients with systemic inflammatory response syndrome (SIRS), IL-8 was independently associated with delirium 56 . These findings suggest that sustained systemic inflammation may contribute to prolong or aggravate brain dysfunction. Stress hyperglycemia, which commonly develops in critically ill patients, also may aggravate sepsis-induced brain injury. In a recent neuropathological study performed in nonsurvivors of critical illness, hyperglycemia was shown to aggravate critical illness-induced neuropathological changes 57 . Patients with uncontrolled hyperglycemia showed increased microglial activation, an important reduction in the density and activation status of astrocytes, increased neuronal damage, and apoptosis in hippocampus and frontal cortex. Most of these abnormalities were virtually absent with normoglycemia. Interestingly, moderate hyperglycemia was shown to be associated with adverse cognitive outcomes in survivors of the acute respiratory distress syndrome 58 . Prolonged hypoxemia also may contribute to brain dysfunction and injury during sepsis. Recently, in a study performed in survivors of prolonged critical illness, a low partial pressure of arterial oxygen during ICU stay was associated with cognitive and psychiatric impairment at 12 months 59 .

Selective vulnerability

Brain lesions in septic shock have been described in areas of the brain susceptible to ischemia (including Ammon’s horn, the frontal junctional cortex, the lenticular nuclei, the dentate nucleus, and the medullary olive), in the hypothalamic nuclei (supraoptic and paraventricular nuclei), the amygdala, the locus coeruleus, and the medullary autonomic nuclei (nucleus tractus solitarii, ambiguous, and parabrachial nuclei) 34 35 . Hippocampal lesions due to inflammatory but also ischemic, hypoxic, or dysglycemic insults 57 60 may explain long-term psychological and cognitive disorders observed in survivors of critical illness 25 61 . Interestingly, reduction of oxidative stress in hippocampus is associated with less cognitive dysfunction in septic rats 52 . There also are arguments for a global brainstem dysfunction during sepsis. First, a recent study suggested that abolition of cough reflex and oculocephalic responses in sedated critically ill patients are associated with death and delirium, respectively 62 . Second, the brainstem nuclei are liable to apoptosis 35 and use of dexmedetomidine, which have antiapoptotic properties 63 , is associated with less delirium in septic patients 64 . Finally, impaired sympathetic control of heart rate is frequent and associated with increased mortality in septic patients suggesting a central autonomic regulatory dysfunction 65 .

Diagnosis

Clinical examination

Clinical examination

Detection of acute brain dysfunction in ICU is based on repeated daily neurological examination. Sepsis-associated encephalopathy is characterized by acute changes in mental status, cognition, alteration of sleep/wake cycle, disorientation, impaired attention, and/or disorganized thinking 66 . Sometimes exaggerated motor activity with agitation, and/or hallucinations can be observed and agitation and somnolence can occur alternatively. Other but less frequent motor symptoms include paratonic rigidity, asterixis, tremor and multifocal myoclonus. Physicians have at their disposal validated clinical instruments for detecting brain dysfunction of critically ill patients, including the Confusion Assessment Method for the ICU (CAM-ICU) 6 , and the intensive care delirium screening checklist (ICDSC) 67 . Once brain dysfunction is identified, an exhaustive neurological examination assessing neck stiffness, motor responses, muscular strength, plantar and deep tendon reflexes and cranial nerves is mandatory. Although the use of sedative drugs may represent a major limitation in the interpretation of clinical findings, a recent study suggested that assessment of brainstem responses is feasible in sedated critically ill patients and loss of selected responses is predictive of mortality and altered mental status 62 . Assessments of plasma levels of brain injury biomarkers, such as neuron specific enolase and S-100 B-protein, have been proposed for detecting brain dysfunction and injury in sedated patients with sepsis 68 69 . Occurrence of sudden fluctuations in mental status unexplained by modification of sedative infusion rate, occurrence of focal neurological sign, seizure(s) and/or neck stiffness should prompt the physician to consider neuroimaging, EEG and/or lumbar puncture to rule out a direct central nervous system infection.

Brain imaging

In case of focal neurological signs, a brain computed tomography should be performed to rule out ischemic or hemorrhagic brain injury 29 34 . Brain MRI should be considered systematically in case of persistent encephalopathy after control of sepsis and exclusion of major confounding factors. With use of diffusion-weighted imaging and gradient echo sequences, this tool has a higher sensitivity than CT for detecting acute CNS disorders, such as recent ischemic or hemorrhagic stroke. Several changes have been described in septic patients (Table 1). Moreover, additionally to the importance of etiological diagnosis, assessment of the nature, and extent of brain damage may also influence patient’s treatment.

<p>Table 1</p>

Brain MRI findings

References

Acute changes

Cytotoxic edema (hippocampus, cortex) ischemic lesions

29 31

Vasogenic edema

29 31

Posterior reversible encephalopathy syndrome (PRES)

30 70

Chronic changes observed in survivors

White matter disruption

71

Brain atrophy

25 72

(frontal cortex, hippocampus)

Brain MRI patterns in sepsis

Electroencephalography

In case of seizure(s), including palpebral myoclonus, an EEG will be required to rule out subtle status epilepticus. Several electrographic patterns have been described in septic patients (Table 2). Sepsis can be associated with electrographic seizures or periodic epileptiform discharges 73 . In a recent study, generalized periodic discharges were strongly associated with nonconvulsive seizures and nonconvulsive status epilepticus 74 . However, the impact of generalized periodic discharges on neurologic outcomes remains to be elucidated. Other EEG abnormalities include increased theta rhythms, triphasic waves and, less often but more pejorative, burst suppression patterns 75 .

<p>Table 2</p>

Electroencephalographic findings

Association with adverse outcome

References

Normal EEG

0

76

Theta (mild generalized slowing)

+

76

Delta (severe slowing)

+

76

Triphasic waves

+

76

Periodic epileptiform discharges

+

73 74 77

Electrographic seizures

++

73

Generalized suppression or burst-suppression

+++

75 76

Electroencephalographic patterns in sepsis

Causes of encephalopathy requiring specific treatment

Standard laboratory tests should be performed systematically to detect and correct common metabolic disturbances that can cause delirium or coma (such as hypoglycemia, hypercalcemia, hypo- or hypernatremia). In addition to sedatives and analgesics, many classes of drugs currently administered in critically ill patients can induce acute brain dysfunction, notably a number of antibiotics, steroids, and cardiac drugs (Table 3).

<p>Table 3</p>

Agent

Mechanism of action

CNS central nervous system.

Benzodiazepines

CNS sedation, neuronal inhibition by membrane hyperpolarization (GABA-agonist)

(long- and short-acting)

Opioids

Anticholinergic toxicity, CNS sedation, fecal impaction

Antibiotics

Inhibition of GABA-A receptors

Penicillins, cephalosporins, carbapenems, Quinolones

Antiarrhythmics

Strong anticholinergic effects, sodium channel blockage, unknown

Flecaïne, Amiodarone, Digoxin

Beta-blockers

Not yet described, association with delirium

Diuretics

Dehydration and electrolyte disturbances

Steroids

Anticholinergic toxicity, Increase of catecholamine activity, GABA-agonist, altered serotonin activity

Inhaled anesthetics

Beta-amyloïd protein generation, cytotoxicity of beta-amyloïd potentiating, apoptosis-inducing

Ketamine

NMDA-antagonism

Histamine-2 blocking agents

Anticholinergic toxicity

Cimetidine

Nonsteroidal anti-inflammatory drugs

Blood–brain-barrier permeability

Anticholinergics

Anticholinergic toxicity

oxybutynin, bladder antispasmodics

Anticonvulsants

CNS Sedation

phenobarbital, phenytoin

Antiparkinsonian agents

Dopaminergic toxicity

L-Dopa, dopamine agonists, amantadine

Antidepressants

Anticholinergic toxicity

(amitriptyline, imipramine, doxepin)

Medications associated with brain dysfunction in the ICU

Benzodiazepines and opioid withdrawal syndromes may represent an important cause of delirium after discontinuation of sedation. Alcohol withdrawal syndrome often is evoked in a patient with a history of alcohol dependence who develops encephalopathy 78 . The predominance of psychomotor agitation and autonomic signs are suggestive of the diagnosis. The benefit of alcohol withdrawal prophylaxis is unproven. Early and aggressive titration of medication guided by symptoms is the only feature associated with improved outcomes. In malnourished or alcoholic patients, Wernicke’s encephalopathy must always be evoked and treated with intravenous thiamine, especially if there is evidence of ophthalmoplegia or ataxia 79 . Thiamine deficiency can be aggravated by infusion of glucose. Tobacco dependency is a risk factor for delirium in critically ill patients, which may be prevented by use of nicotine patch in chronic smokers 80 . Numerous iatrogenic and/or environmental factors also may aggravate brain dysfunction, such as use of physical restraints, excessive noise, or underexposure to light in the ICU 81 82 .

In a patient with unexplained neurologic symptoms (focal neurologic sign or encephalopathy) and bloodstream infection, infective endocarditis should be systematically ruled out as this condition often is associated with neurologic complications 83 . Of note, endocarditis has to be ruled out in the presence of cerebral microbleeds on MRI 84 . Finally, air embolism is an iatrogenic cause of sudden coma, agitation, seizure, or focal neurological signs, and for which hyperbaric oxygen is recommended. It must be emphasized that SAE often is a multifactorial condition. Finally, reappearance or persistence of encephalopathy may indicate that sepsis is not controlled.

Outcomes

Eidelman et al. showed in a landmark study that approximately one-third of patients with sepsis had a Glasgow coma scale less than 12 and that alteration of alertness and consciousness was an independent prognosis factor, increasing mortality rate up to 63% when Glasgow coma scale drops below 8 1 . More recent studies have shown that in addition to being highly prevalent in the ICU, delirium is an independent risk factor for threefold increase in mortality, with elderly patients being at an increased risk 7 . Number of days of ICU delirium was associated with higher 1-year mortality after adjustment for relevant covariates in an older ICU population 85 . Mortality also increases with severity of electrophysiological abnormalities, ranging from 0 when EEG is interpreted as normal to 67% when it shows burst suppressions 73 76 . Electrographic seizures and periodic discharges also are associated with increased mortality 29 73 74 75 . The prognosis value of MRI findings remains to be assessed 29 . The impact of brain dysfunction during sepsis on secondary outcomes is not known but is certainly close to that reported for delirium in critically ill patients, including prolonged length of stay in ICU and hospital, a longer duration of mechanical ventilation and at an extra cost 7 86 . Severe sepsis also is independently associated with substantial and persistent new cognitive impairment and functional disability 87 . A cognitive deficit also has been reported in survivors from the acute respiratory distress syndrome 88 89 90 . Interestingly, it has been shown that an elevated level of amyloid-beta in intensive care patients with delirium correlates with long-term cognitive impairment 56 . In addition, hippocampal atrophy may represent a determinant of neuropsychological sequelae 25 , including depression, anxiety, and posttraumatic stress syndrome 91 .

Therapeutic perspectives

Because there is no specific treatment for SAE yet, treatment should focus on control of infection source and supportive measures, such as management of organ failure(s), prevention of metabolic disturbances, and avoidance of neurotoxic drugs. Preventive strategies to reduce occurrence and duration of brain dysfunction should be applied for every patient admitted to the ICU (Table 4). Symptomatic treatment of delirium and agitation does not differ from that propose in critically ill patients and has been described elsewhere 92 . Adjunctive therapies of septic shock may protect the BBB or reduce endothelial activation, but their effect has not been established. For instance, activated protein C in septic shock patients with impaired consciousness significantly reduced plasma levels of S100-β protein 93 . Steroids have been shown to reduce posttraumatic stress syndrome 94 and prevention of prolonged hyperglycemia also may be neuroprotective 57 .

<p>Table 4</p>

Pharmacological measures

Type of study

References

RCT randomized controlled trial.

Reduce use of benzodiazepines and opioids

Observational studies

44 95

Perform daily sedation stops

RCT

96 97

Use dexmedetomidine (versus benzodiazepines or propofol) as sedative

RCT

46 47 98

Pain assessment: sedation – analgesia – delirium protocol

Observational studies

99 100

Prevention of metabolic disturbances (severe hypoxemia, fever, dysnatremia(s), prolonged hyperglycemia…)

Observational studies

4 54 57 59 101

Nonpharmacological measures

Sleep protocol

RCT (non-critical care setting)

102

Reorientation and cognitively stimulating activities

Rehydration

Use of eyeglasses, magnifying lenses, and hearing aids

Avoid use of physical restraints

Observational studies

82 103

Early mobilization

RCT

104

Potential strategies to reduce brain dysfunction in ICU patients

Various therapeutic interventions have been experimentally tested. Inhibition of iNOS reduces neuronal apoptosis in septic animals but does not improve the state of consciousness and may even aggravate ischemic injuries of the brain 105 . Another study showed that sepsis-induced cognitive impairment at 2 months was prevented in iNOS knockout mice 24 . Experimental studies show a protective effect on the BBB with the use of magnesium 106 107 , riluzole 107 , hyperbaric oxygen therapy 108 , calcium channel blockers, steroids, or anticytokine antibodies 109 . Intravenous immunoglobulins, administered before cecal ligation and perforation, seem to preserve BBB integrity 110 . Regarding oxidative stress, antioxidant treatment with N-acetylcysteine and deferoxamine prevents cognitive impairment in septic mice 52 .

Conclusions

Brain dysfunction is frequent in sepsis but too often neglected, despite its dramatic impact on outcomes. Its pathophysiology is highly complex, resulting from both inflammatory and noninflammatory processes that affect all types of brain cells. The diagnosis of encephalopathy relies essentially on neurological examination, which can lead to specific neurological tests, including EEG and neuroimaging. Brain dysfunction during sepsis is frequently entwined with others factors that have to be screened systematically, including withdrawal syndrome, drugs overdose, and severe metabolic disturbances. Currently, the treatment of sepsis-associated encephalopathy mainly consists of general management of sepsis and prevention of aggravating factors, including metabolic disturbances, drug overdoses, anticholinergic medications, withdrawal syndromes, and Wernicke’s encephalopathy. In the future, investigations should be undertaken to reduce the duration of brain dysfunction and to study the impact of this reduction on important health outcomes, including mortality and functional and cognitive status in survivors. Modulation of microglial activation, prevention of BBB alterations, and use of antioxidants represent relevant therapeutic targets that may impact significantly on neurologic outcomes.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

RS, FV, CR and TS wrote the manuscript. IFK, MW, DA, FC reviewed the manuscript. All authors read and approved the final manuscript.

<p>The spectrum of septic encephalopathy. Definitions, etiologies, and mortalities</p>EidelmanLAPuttermanDPuttermanCSprungCLJAMA199627547047310.1001/jama.1996.035303000540408627969<p>Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration systemic sepsis cooperative study group</p>SprungCLPeduzziPNShatneyCHScheinRMWilsonMFSheagrenJNHinshawLBCrit Care Med19901880180610.1097/00003246-199008000-000012379391<p>Potential mechanisms and markers of critical illness-associated cognitive dysfunction</p>MilbrandtEBAngusDCCurr Opin Crit Care20051135535910.1097/01.ccx.0000170508.63067.0416015116<p>A prospective study of agitation in a medical-surgical ICU: incidence, risk factors, and outcomes</p>JaberSChanquesGAltairacCSebbaneMVergneCPerrigaultPFEledjamJJChest20051282749275710.1378/chest.128.4.274916236951<p>Hyperactive delirium and blood glucose control in critically ill patients</p>HeymannASanderMKrahneDDejaMWeber-CarstensSMacGuillMKastrupMWerneckeKDNachtigallISpiesCDJ Int Med Res20073566667710.1177/14732300070350051117900406<p>Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU)</p>ElyEWInouyeSKBernardGRGordonSFrancisJMayLTrumanBSperoffTGautamSMargolinRJAMA20012862703271010.1001/jama.286.21.270311730446<p>Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit</p>ElyEWShintaniATrumanBSperoffTGordonSMHarrellFEJrInouyeSKBernardGRDittusRSJAMA20042911753176210.1001/jama.291.14.175315082703<p>The inflammatory reflex</p>TraceyKJNature200242085385910.1038/nature0132112490958<p>Endocrine effects of vasopressin in critically ill patients</p>SharsharTAnnaneDBest Pract Res Clin Anaesthesiol20082226527310.1016/j.bpa.2008.02.00518683473<p>Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism</p>SemmlerAHermannSMormannFWeberpalsMPaxianSAOkullaTSchafersMKummerMPKlockgetherTHenekaMTJ Neuroinflammation200853810.1186/1742-2094-5-38255376418793399<p>Synaptic scaling mediated by glial TNF-alpha</p>StellwagenDMalenkaRCNature20064401054105910.1038/nature0467116547515<p>Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline</p>TerrandoNMonacoCMaDFoxwellBMFeldmannMMazeMProc Natl Acad Sci USA2010107205182052210.1073/pnas.1014557107299666621041647<p>The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction</p>TerrandoNRei FidalgoAVizcaychipiMCibelliMMaDMonacoCFeldmannMMazeMCrit Care201014R8810.1186/cc9019291172220470406<p>HMGB1 mediates cognitive impairment in sepsis survivors</p>ChavanSSHuertaPTRobbiatiSValdes-FerrerSIOchaniMDanchoMFrankfurtMVolpeBTTraceyKJDiamondBMol Med201218930937345947322634723<p>Systemic infection and delirium: when cytokines and acetylcholine collide</p>van GoolWAvan de BeekDEikelenboomPLancet201037577377510.1016/S0140-6736(09)61158-220189029<p>Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines</p>HenryCJHuangYWynneAMGodboutJPBrain Behav Immun20092330931710.1016/j.bbi.2008.09.002269298618814846<p>Endotoxin-induced systemic inflammation activates microglia: [(11)C]PBR28 positron emission tomography in nonhuman primates</p>HannestadJGallezotJDSchafbauerTLimKKloczynskiTMorrisEDCarsonREDingYSCosgroveKNeuroimage20126323223910.1016/j.neuroimage.2012.06.05522776451<p>Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system</p>ChenJBuchananJBSparkmanNLGodboutJPFreundGGJohnsonRWBrain Behav Immun20082230131110.1016/j.bbi.2007.08.014237491917951027<p>Peripheral infection and aging interact to impair hippocampal memory consolidation</p>BarrientosRMHigginsEABiedenkappJCSprungerDBWright-HardestyKJWatkinsLRRudyJWMaierSFNeurobiol Aging20062772373210.1016/j.neurobiolaging.2005.03.01015893410<p>Interleukin-1beta causes long-term potentiation deficiency in a mouse model of septic encephalopathy</p>ImamuraYWangHMatsumotoNMuroyaTShimazakiJOguraHShimazuTNeuroscience2011187636921571042<p>Role of interleukin-1beta in postoperative cognitive dysfunction</p>CibelliMFidalgoARTerrandoNMaDMonacoCFeldmannMTakataMLeverIJNanchahalJFanselowMSMazeMAnn Neurol20106836036810.1002/ana.2208220818791<p>Systemic inflammation induces apoptosis with variable vulnerability of different brain regions</p>SemmlerAOkullaTSastreMDumitrescu-OzimekLHenekaMTJ Chem Neuroanat20053014415710.1016/j.jchemneu.2005.07.00316122904<p>Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model</p>SemmlerAFrischCDebeirTRamanathanMOkullaTKlockgetherTHenekaMTExp Neurol200720473374010.1016/j.expneurol.2007.01.00317306796<p>NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits</p>WeberpalsMHermesMHermannSKummerMPTerwelDSemmlerABergerMSchafersMHenekaMTJ Neurosci200929141771418410.1523/JNEUROSCI.3238-09.200919906966<p>Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors</p>SemmlerAWidmannCNOkullaTUrbachHKaiserMWidmanGMormannFWeideJFliessbachKHoeftAJ Neurol Neurosurg Psychiatry201384626910.1136/jnnp-2012-30288323134661<p>Role of endothelial nitric oxide synthase-derived nitric oxide in activation and dysfunction of cerebrovascular endothelial cells during early onsets of sepsis</p>HandaOStephenJCepinskasGAm J Physiol Heart Circ Physiol2008295H1712171910.1152/ajpheart.00476.2008259350618723768<p>Cerebral autoregulation is influenced by carbon dioxide levels in patients with septic shock</p>TacconeFSCastanares-ZapateroDPeres-BotaDVincentJLBerreJMelotCNeurocrit Care201012354210.1007/s12028-009-9289-619806473<p>TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1</p>AlexanderJJJacobACunninghamPHensleyLQuiggRJNeurochem Int20085244745610.1016/j.neuint.2007.08.006319146517884256<p>Brain lesions in septic shock: a magnetic resonance imaging study</p>SharsharTCarlierRBernardFGuidouxCBroulandJPNardiOde la GrandmaisonGLAboabJGrayFMenonDAnnaneDIntensive Care Med20073379880610.1007/s00134-007-0598-y17377766<p>Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings</p>FugateJEClaassenDOCloftHJKallmesDFKozakOSRabinsteinAAMayo Clin Proc20108542743210.4065/mcp.2009.0590286197120435835<p>Sepsis-associated encephalopathy: a magnetic resonance imaging and spectroscopy study</p>BozzaFAGarteiserPOliveiraMFDoblasSCranfordRSaundersDJonesITownerRACastro-Faria-NetoHCJ Cereb Blood Flow Metab20103044044810.1038/jcbfm.2009.215294913219844239<p>Plasma tryptophan and tyrosine levels are independent risk factors for delirium in critically ill patients</p>PandharipandePPMorandiAAdamsJRGirardTDThompsonJLShintaniAKElyEWIntensive Care Med2009351886189210.1007/s00134-009-1573-619588122<p>The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness*</p>Adams WilsonJRMorandiAGirardTDThompsonJLBoomershineCSShintaniAKElyEWPandharipandePPCrit Care Med20124083584110.1097/CCM.0b013e318236f62d362566622080637<p>The neuropathology of septic shock</p>SharsharTAnnaneDde la GrandmaisonGLBroulandJPHopkinsonNSFrancoiseGBrain Pathol200414213314997934<p>Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock</p>SharsharTGrayFLorin de la GrandmaisonGHopkinsonNSRossEDorandeuAOrlikowskiDRaphaelJCGajdosPAnnaneDLancet20033621799180510.1016/S0140-6736(03)14899-414654318<p> <b>Cerebral perfusion in sepsis-associated delirium</b> </p>PfisterDSiegemundMDell-KusterSSmielewskiPRueggSStrebelSPMarschSCParggerHSteinerLACrit Care200812R6310.1186/cc6891248144418457586<p>Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence</p>HshiehTTFongTGMarcantonioERInouyeSKJ Gerontol A Biol Sci Med Sci20086376477210.1093/gerona/63.7.764291779318693233<p>Effects of isoflurane on prefrontal acetylcholine release and hypothalamic Fos response in young adult and aged rats</p>JanssonAOlinKYoshitakeTHagmanBHerringtonMKKehrJPermertJExp Neurol200419053554310.1016/j.expneurol.2004.08.02715530892<p>Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: reconciling inflammatory and cholinergic hypotheses of delirium</p>FieldRHGossenACunninghamCJ Neurosci2012326288629410.1523/JNEUROSCI.4673-11.2012335961722553034<p>An alteration in the gamma-aminobutyric acid receptor system in experimentally induced septic shock in rats</p>KadoiYSaitoSCrit Care Med19962429830510.1097/00003246-199602000-000208605805<p>Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia</p>PavlovVAOchaniMGallowitsch-PuertaMOchaniKHustonJMCzuraCJAl-AbedYTraceyKJProc Natl Acad Sci USA20061035219522310.1073/pnas.0600506103140562616549778<p>Amino acid imbalance early in septic encephalopathy</p>BaslerTMeier-HellmannABredleDReinhartKIntensive Care Med20022829329810.1007/s00134-002-1217-611904658<p>Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial</p>van EijkMMRoesKCHoningMLKuiperMAKarakusAvan der JagtMSpronkPEvan GoolWAvan der MastRCKeseciogluJSlooterAJLancet20103761829183710.1016/S0140-6736(10)61855-721056464<p>Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients</p>PandharipandePShintaniAPetersonJPunBTWilkinsonGRDittusRSBernardGRElyEWAnesthesiology2006104212610.1097/00000542-200601000-0000516394685<p>Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial</p>PandharipandePPSandersRDGirardTDMcGraneSThompsonJLShintaniAKHerrDLMazeMElyEWCrit Care201014R3810.1186/cc8916288714520233428<p>Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial</p>PandharipandePPPunBTHerrDLMazeMGirardTDMillerRRShintaniAKThompsonJLJacksonJCDeppenSAJAMA20072982644265310.1001/jama.298.22.264418073360<p>Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials</p>JakobSMRuokonenEGroundsRMSarapohjaTGarrattCPocockSJBrattyJRTakalaJJAMA20123071151116010.1001/jama.2012.30422436955<p>Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions</p>DahmaniSRouelleDGressensPMantzJAnesthesiology200510396997710.1097/00000542-200511000-0001116249671<p>Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation</p>DahmaniSRouelleDGressensPMantzJAnesthesiology201011237338310.1097/ALN.0b013e3181ca698220098140<p>Neuroprotective effects of dexmedetomidine against glutamate agonist-induced neuronal cell death are related to increased astrocyte brain-derived neurotrophic factor expression</p>DegosVCharpentierTLChhorVBrissaudOLebonSSchwendimannLBednareckNPassemardSMantzJGressensPAnesthesiology20131181123113210.1097/ALN.0b013e318286cf3623353792<p>Oxidative variables in the rat brain after sepsis induced by cecal ligation and perforation</p>BarichelloTFortunatoJJVitaliAMFeierGReinkeAMoreiraJCQuevedoJDal-PizzolFCrit Care Med20063488688910.1097/01.CCM.0000201880.50116.1216505668<p>Antioxidant treatment prevented late memory impairment in an animal model of sepsis</p>BarichelloTMachadoRAConstantinoLValvassoriSSReusGZMartinsMRPetronilhoFRitterCQuevedoJDal-PizzolFCrit Care Med2007352186219010.1097/01.CCM.0000281452.60683.9617855835<p>Caspase-3 mediates in part hippocampal apoptosis in sepsis</p>ComimCMBarichelloTGrandgirardDDal-PizzolFQuevedoJLeibSLComimCMBarichelloTGrandgirardDDal-PizzolFQuevedoJLeibSLMol Neurobiol2013473948<p>Hyperglycaemia and apoptosis of microglial cells in human septic shock</p>PolitoABroulandJPPorcherRSonnevilleRSiamiSStevensRDGuidouxCMaximeVde la GrandmaisonGLChretienFCCrit Care201115R13110.1186/cc10244321899721612615<p>Procalcitonin and C-reactive protein levels at admission as predictors of duration of acute brain dysfunction in critically ill patients</p>McGraneSGirardTDThompsonJLShintaniAKWoodworthAElyEWPandharipandePPCrit Care201115R7810.1186/cc10070321933021366899<p>Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients</p>van den BoogaardMKoxMQuinnKLvan AchterbergTvan der HoevenJGSchoonhovenLPickkersPCrit Care201115R29710.1186/cc10598338864922206727<p>Impact of hyperglycemia on neuropathological alterations during critical illness</p>SonnevilleRden HertogHMGuizaFGunstJDereseIWoutersPJBroulandJPPolitoAGrayFChretienFJ Clin Endocrinol Metab2012972113212310.1210/jc.2011-297122442271<p>Blood glucose dysregulation and cognitive outcome in ARDS survivors</p>HopkinsROSuchytaMRSnowGLJephsonAWeaverLKOrmeJFBrain Inj2010241478148410.3109/02699052.2010.50686120858026<p>The ARDS Cognitive Outcomes Study (ACOS): long-term neuropsychological function in acute lung injury survivors</p>MikkelsenMEChristieJDLankenPNBiesterRCThompsonBTBellamySLLocalioARDemissieEHopkinsROAngusDCAm J Respir Crit Care Med201218513071510.1164/rccm.201111-2025OC22492988<p>Brain autopsy findings in intensive care unit patients previously suffering from delirium: a pilot study</p>JanzDRAbelTWJacksonJCGuntherMLHeckersSElyEWJ Crit Care201025538e537512<p>Delirium as a predictor of long-term cognitive impairment in survivors of critical illness</p>GirardTDJacksonJCPandharipandePPPunBTThompsonJLShintaniAKGordonSMCanonicoAEDittusRSBernardGRElyEWCrit Care Med2010381513152010.1097/CCM.0b013e3181e47be1363881320473145<p>Brainstem responses can predict death and delirium in sedated patients in intensive care unit</p>SharsharTPorcherRSiamiSRohautBBailly-SalinJHopkinsonNSClairBGuidouxCIacoboneESonnevilleRCrit Care Med2011391960196710.1097/CCM.0b013e31821b843b21532477<p>The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats</p>EngelhardKWernerCEberspacherEBachlMBlobnerMHildtEHutzlerPKochsEAnesth Analg200396524531table of contents12538207<p>Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial</p>PandharipandePPSandersRDGirardTDMcGraneSThompsonJLShintaniAKHerrDLMazeMElyEWCrit Care200714R38<p>Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach</p>AnnaneDTraboldFSharsharTJarrinIBlancASRaphaelJCGajdosPAm J Respir Crit Care Med199916045846510.1164/ajrccm.160.2.981007310430714<p>Sepsis-associated encephalopathy and its differential diagnosis</p>IacoboneEBailly-SalinJPolitoAFriedmanDStevensRDSharsharTCrit Care Med200937S33133620046118<p>Intensive Care Delirium Screening Checklist: evaluation of a new screening tool</p>BergeronNDuboisMJDumontMDialSSkrobikYIntensive Care Med2001278596410.1007/s00134010090911430542<p>Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis</p>PiazzaORussoECotenaSEspositoGTufanoRBr J Anaesth20079951852110.1093/bja/aem20117650519<p>Elevated serum levels of S-100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock</p>NguyenDNSpapenHSuFSchiettecatteJShiLHachimi-IdrissiSHuyghensLCrit Care Med2006341967197410.1097/01.CCM.0000217218.51381.4916607230<p>Posterior reversible encephalopathy syndrome in infection, sepsis, and shock</p>BartynskiWSBoardmanJFZeiglerZRShadduckRKListerJAJNR Am J Neuroradiol2006272179219017110690<p>The relationship between delirium duration, white matter integrity, and cognitive impairment in intensive care unit survivors as determined by diffusion tensor imaging: the VISIONS prospective cohort magnetic resonance imaging study*</p>MorandiARogersBPGuntherMLMerkleKPandharipandePGirardTDJacksonJCThompsonJShintaniAKGeevargheseSCrit Care Med2012402182218910.1097/CCM.0b013e318250acdc22584766<p>The association between brain volumes, delirium duration, and cognitive outcomes in intensive care unit survivors: the VISIONS cohort magnetic resonance imaging study*</p>GuntherMLMorandiAKrauskopfEPandharipandePGirardTDJacksonJCThompsonJShintaniAKGeevargheseSMillerRR3rdCrit Care Med2012402022203210.1097/CCM.0b013e318250acc022710202<p>Continuous electroencephalography in the medical intensive care unit</p>OddoMCarreraEClaassenJMayerSAHirschLJCrit Care Med2009372051205610.1097/CCM.0b013e3181a0060419384197<p>Generalized periodic discharges in the critically ill: a case–control study of 200 patients</p>ForemanBClaassenJAbou KhaledKJirschJAlschulerDMWittmanJEmersonRGHirschLJNeurology2012791951196010.1212/WNL.0b013e3182735cd723035068<p>Presence of electroencephalogram burst suppression in sedated, critically ill patients is associated with increased mortality</p>WatsonPLShintaniAKTysonRPandharipandePPPunBTElyEWCrit Care Med2008363171317710.1097/CCM.0b013e318186b9ce19020432<p>The electroencephalogram in sepsis-associated encephalopathy</p>YoungGBBoltonCFArchibaldYMAustinTWWellsGAJ Clin Neurophysiol1992914515210.1097/00004691-199201000-000161552002<p>Impact of prolonged periodic epileptiform discharges on coma prognosis</p>OngCGilmoreEClaassenJForemanBMayerSANeurocrit Care201217394410.1007/s12028-012-9728-722700361<p>Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary</p>AwissiDKLebrunGCoursinDBRikerRRSkrobikYIntensive Care Med201339163010.1007/s00134-012-2758-y23184039<p>Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management</p>SechiGSerraALancet Neurol2007644245510.1016/S1474-4422(07)70104-717434099<p>Nicotine withdrawal and agitation in ventilated critically ill patients</p>LucidarmeOSeguinADaubinCRamakersMTerziNBeckPCharbonneauPdu CheyronDCrit Care201014R5810.1186/cc8954288717920380688<p>Intensive care unit environment may affect the course of delirium</p>ZaalIJSpruytCFPeelenLMvan EijkMMWientjesRSchneiderMMKeseciogluJSlooterAJIntensive Care Med20123948148823093246<p>Delirium in the cardiovascular ICU: exploring modifiable risk factors</p>McPhersonJAWagnerCEBoehmLMHallJDJohnsonDCMillerLRBurnsKMThompsonJLShintaniAKElyEWPandharipandePPCrit Care Med201241405413<p>Neurologic complications and outcomes of infective endocarditis in critically ill patients: the ENDOcardite en REAnimation prospective multicenter study</p>SonnevilleRMirabelMHajageDTubachFVignonPPerezPLavoueSKouatchetAPajotODessapAMCrit Care Med2011391474148110.1097/CCM.0b013e3182120b4121358398<p>Cerebral microbleeds are frequent in infective endocarditis: a case–control study</p>KleinIIungBLabreucheJHessAWolffMMessika-ZeitounDLavalleePLaissyJPLeportCDuvalXStroke2009403461346510.1161/STROKEAHA.109.56254619762695<p>Days of delirium are associated with 1-year mortality in an older intensive care unit population</p>PisaniMAKongSYKaslSVMurphyTEAraujoKLVan NessPHAm J Respir Crit Care Med20091801092109710.1164/rccm.200904-0537OC278441419745202<p>Costs associated with delirium in mechanically ventilated patients</p>MilbrandtEBDeppenSHarrisonPLShintaniAKSperoffTStilesRATrumanBBernardGRDittusRSElyEWCrit Care Med20043295596210.1097/01.CCM.0000119429.16055.9215071384<p>Long-term cognitive impairment and functional disability among survivors of severe sepsis</p>IwashynaTJElyEWSmithDMLangaKMJAMA20103041787179410.1001/jama.2010.1553334528820978258<p>Quality of life, emotional abnormalities, and cognitive dysfunction in survivors of acute lung injury/acute respiratory distress syndrome</p>HopkinsROHerridgeMSClin Chest Med200627679689abstract x10.1016/j.ccm.2006.06.00317085255<p>Assessing neurocognitive outcomes after critical illness: are delirium and long-term cognitive impairments related?</p>HopkinsROJacksonJCCurr Opin Crit Care20061238839410.1097/01.ccx.0000244115.24000.f516943714<p>Short- and long-term cognitive outcomes in intensive care unit survivors</p>HopkinsROJacksonJCClin Chest Med200930143153ix10.1016/j.ccm.2008.11.00119186286<p>Factors associated with posttraumatic stress symptoms in a prospective cohort of patients after abdominal sepsis: a nomogram</p>BoerKRvan RulerOvan EmmerikAASprangersMAde RooijSEVroomMBde BorgieCABoermeesterMAReitsmaJBIntensive Care Med20083466467410.1007/s00134-007-0941-3227107918197398<p>Delirium in the intensive care unit</p>GirardTDPandharipandePPElyEWCrit Care200812Suppl 3S310.1186/cc6149260711319105796<p>Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock</p>SpapenHNguyenDNTroubleynJHuyghensLSchiettecatteJCrit Care201014R5410.1186/cc8947288717220374626<p>Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery</p>SchellingGRoozendaalBKrauseneckTSchmoelzMDEQDBriegelJAnn N Y Acad Sci20061071465310.1196/annals.1364.00516891561<p>Incidence, risk factors and consequences of ICU delirium</p>OuimetSKavanaghBPGottfriedSBSkrobikYIntensive Care Med200733667310.1007/s00134-006-0399-817102966<p>Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation</p>KressJPPohlmanASO’ConnorMFHallJBN Engl J Med20003421471147710.1056/NEJM20000518342200210816184<p>Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial</p>GirardTDKressJPFuchsBDThomasonJWSchweickertWDPunBTTaichmanDBDunnJGPohlmanASKinniryPALancet200837112613410.1016/S0140-6736(08)60105-118191684<p>Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial</p>RikerRRShehabiYBokeschPMCerasoDWisemandleWKouraFWhittenPMargolisBDByrneDWElyEWRochaMGJAMA200930148949910.1001/jama.2009.5619188334<p>Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: a post Hoc analysis of the DOLOREA study</p>PayenJFBossonJLChanquesGMantzJLabarereJAnesthesiology20091111308131610.1097/ALN.0b013e3181c0d4f019934877<p>I-SAVE study: impact of sedation, analgesia, and delirium protocols evaluated in the intensive care unit: an economic evaluation</p>AwissiDKBeginCMoisanJLachaineJSkrobikYAnn Pharmacother201246212810.1345/aph.1Q28422202496<p>Severe agitation among ventilated medical intensive care unit patients: frequency, characteristics and outcomes</p>WoodsJCMionLCConnorJTVirayFJahanLHuberCMcHughRGonzalesJPStollerJKArroligaACIntensive Care Med2004301066107210.1007/s00134-004-2193-914966671<p>A multicomponent intervention to prevent delirium in hospitalized older patients</p>InouyeSKBogardusSTJrCharpentierPALeo-SummersLAcamporaDHolfordTRCooneyLMJrN Engl J Med199934066967610.1056/NEJM19990304340090110053175<p>Delirium as detected by the CAM-ICU predicts restraint use among mechanically ventilated medical patients</p>MicekSTAnandNJLaibleBRShannonWDKollefMHCrit Care Med2005331260126510.1097/01.CCM.0000164540.58515.BF15942341<p>Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial</p>SchweickertWDPohlmanMCPohlmanASNigosCPawlikAJEsbrookCLSpearsLMillerMFranczykMDeprizioDLancet20093731874188210.1016/S0140-6736(09)60658-919446324<p>Selective inducible nitric oxide inhibition can restore hemodynamics, but does not improve neurological dysfunction in experimentally-induced septic shock in rats</p>KadoiYGotoFAnesth Analg20049921222010.1213/01.ANE.0000118111.94913.2215281532<p>Effect of magnesium sulfate administration on blood–brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study</p>EsenFErdemTAktanDOrhanMKayaMEraksoyHCakarNTelciLCrit Care20059R182310.1186/cc3004106510415693962<p>The effects of riluzole on neurological, brain biochemical, and histological changes in early and late term of sepsis in rats</p>TokluHZUysalMKKabasakalLSirvanciSErcanFKayaMJ Surg Res200915223824810.1016/j.jss.2008.03.01318718604<p>The effects of hyperbaric oxygen therapy on blood–brain barrier permeability in septic rats</p>AvtanSMKayaMOrhanNArslanAAricanNTokluASGursesCElmasIKucukMAhishaliBBrain Res20111412637221803336<p>Therapeutic approaches to reduce systemic inflammation in septic-associated neurologic complications</p>WrattenMLEur J Anaesthesiol Suppl2008421718289409<p>Intravenous immunoglobulins prevent the breakdown of the blood–brain barrier in experimentally induced sepsis</p>EsenFSenturkEOzcanPEAhishaliBAricanNOrhanNEkizogluOKucukMKayaMCrit Care Med2012401214122010.1097/CCM.0b013e31823779ca22202704